KRAS and non-small cell lung carcinoma: Blumenschein et al. reported a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC but concluded that the PFS and response rate of patients with previously treated KRAS-mutant-positive NSCLC were similar to those of patients with docetaxel.